Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cytokinetics Inc (NASDAQ:CYTK)

7.94
Delayed Data
As of 1:17pm ET
 -0.14 / -1.73%
Today’s Change
5.51
Today|||52-Week Range
13.18
-24.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$320.0M

Company Description

Cytokinetics, Inc. is a late-stage biopharmaceutical company, which focuses on the discovery and developments of first-in-class muscle activators as potential treatment for debilitating diseases in which muscle performance is compromised and declining. Its research and development activities relating to the biology of muscle function have evolved from their knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Contact Information

Cytokinetics, Inc.
280 East Grand Avenue
South San Francisco California 94080
P:(650) 624-3000
Investor Relations:
(650) 624-3060

Employees

Shareholders

Individual stakeholders7.58%
Other institutional52.67%
Mutual fund holders24.01%

Top Executives

Robert I. BlumPresident, Chief Executive Officer & Director
Sharon A. BarbariChief Financial Officer, Secretary & Executive VP
Fady Ibraham MalikExecutive Vice President-Research & Development
Andy WolffChief Medical Officer & Senior Vice President
Bonnie A. CharpentierSenior VP-Regulatory Affairs & Compliance